SCHEMBL2540148

SCHEMBL2540148

COc1cc2c(/C=C/[N+](=O)[O-])c[nH]c2cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.44
ALDH1A1 P00352 4/20 0.43
MAPT P10636 3/20 0.43
LMNA P02545 2/20 0.43
MAPK1 P28482 2/20 0.43
HTT P42858 2/20 0.43
MITF O75030 1/20 0.43
HSP90AA1 P07900 1/20 0.43
PRMT1 Q99873 1/20 0.43
HTR2B P41595 1/20 0.43
VCP P55072 3/20 0.42
MTNR1A P48039 3/20 0.41
MTNR1B P49286 2/20 0.39
GALR2 O43603 1/20 0.39
EGFR P00533 1/20 0.39
SYK P43405 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2540150 1.00 HTR1A (0.44) HTR1AALDH1A1MAPTLMNAMAPK1
SCHEMBL31236295 0.87 ALDH1A1 (0.43) ALDH1A1MAPTLMNAMAPK1HTT
SCHEMBL2536056 0.85 GPR84 (0.41) MAPTMAPK1VCPNPSR1KMT2A
SCHEMBL2536059 0.85 GPR84 (0.41) MAPTMAPK1VCPNPSR1KMT2A
SCHEMBL2539844 0.85 MAPT (0.43) ALDH1A1MAPTLMNAMAPK1HTT
SCHEMBL2539842 0.85 MAPT (0.43) ALDH1A1MAPTLMNAMAPK1HTT
SCHEMBL5150461 0.84 ALDH1A1 (0.41) ALDH1A1MAPTLMNAMAPK1HTT
SCHEMBL5150456 0.84 ALDH1A1 (0.41) ALDH1A1MAPTLMNAMAPK1HTT
SCHEMBL25425526 0.80 GPR84 (0.40) ALDH1A1MAPTLMNAHTTHSP90AA1
SCHEMBL5644085 0.80 HTR2B (0.46) HTR1AALDH1A1MAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1859798-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2015-12-30 EP disclosed
US-8044090-B2 N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor ELI LILLY (US) 2011-10-25 US disclosed
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2009-12-10 US disclosed
EP-1379239-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2007-09-12 EP disclosed
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2007-05-03 US disclosed
US-7157488-B2 N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor ELI LILLY AND COMPANY (US) 2007-01-02 US disclosed
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 US disclosed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 EP disclosed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B HTR1A 6/4885ALDH1A1 1218/4885MAPT 3701/4885
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B HTR1A 6/4885ALDH1A1 1218/4885MAPT 3701/4885
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B HTR1A 6/4885ALDH1A1 1218/4885MAPT 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.